Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2022; 10(33): 12156-12163
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12156
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12156
Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C
Sha-Sha Sun, Wen-Dong Li, Jing-Long Chen, Department of Oncology, Capital Medical University Affiliated Beijing Ditan Hospital, Beijing 100015, China
Author contributions: Sun SS, Li WD and Chen JL design the experiment, collected the data; Li WD and Chen JL analysed data; Sun SS wrote and revised the manuscript.
Institutional review board statement: The study was reviewed and approved by Beijing Ditan Hospital Affiliated to Capital Medical University Institutional Review Board (Approval No. 013-03).
Informed consent statement: Informed consent was obtained from all individual participants included in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing-Long Chen, MS, Associate Professor, Department of Oncology, Capital Medical University Affiliated Beijing Ditan Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. hhh540027@126.com
Received: August 13, 2022
Peer-review started: August 13, 2022
First decision: September 23, 2022
Revised: September 29, 2022
Accepted: October 24, 2022
Article in press: October 24, 2022
Published online: November 26, 2022
Processing time: 102 Days and 9.1 Hours
Peer-review started: August 13, 2022
First decision: September 23, 2022
Revised: September 29, 2022
Accepted: October 24, 2022
Article in press: October 24, 2022
Published online: November 26, 2022
Processing time: 102 Days and 9.1 Hours
Core Tip
Core Tip: Few reports have focused on the effect of transarterial chemoembolization and radiofrequency ablation (TACE-RFA) in patients with large hepatocellular carcinoma (HCC) of barcelona clinic liver cancer (BCLC) stage C. Thus, the aim of this retrospective study was to evaluate the safety and efficacy of a combined therapy strategy with TACE-RFA in large HCC of BCLC C group. We found that TACE-RFA had an advantage over TACE alone in improving overall survival in large HCC patients with BCLC C.